Heparanase enhances tumor growth and chemoresistance by promoting autophagy

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3946-3957

  Shteingauz, Anna ^a   Boyango, Ilanit ^a   Naroditsky, Inna ^b   Hammond, Edward ^c   Gruber, Maayan ^d   Doweck, Ilana ^d   Ilan, Neta ^a   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Rambam Health Care Campus ^*  (Israel)

^c Progen Pharmaceuticals Limited   (Australia)

^d CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HEPARANASE; HEPARANASE INHIBITOR; PG 545; UNCLASSIFIED DRUG; AMINO ACID; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; CISPLATIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MEMBRANE LIPID; MULTIPROTEIN COMPLEX; PHOSPHATIDYLETHANOLAMINE; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; C6 CELL LINE; CANCER CELL LINE; CANCER RESISTANCE; CARCINOGENICITY; CELL STRESS; CONTROLLED STUDY; ENZYME ACTIVITY; FADU CELL LINE; GLIOMA; HUMAN; HUMAN CELL; LARYNX CARCINOMA; MOUSE MODEL; NONHUMAN; PHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIHN 013 CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; U87 CELL LINE; ANIMAL; CARCINOMA; CELL CULTURE; CELL DIVISION; DEFICIENCY; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; FIBROBLAST; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PHAGOSOME; PHARYNX CANCER; PHYSIOLOGY; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; XENOGRAFT;

AMINO ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARCINOMA; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; CHLOROQUINE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLASTS; GLIOMA; GLUCURONIDASE; HETEROGRAFTS; HUMANS; MEMBRANE LIPIDS; MICE; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; PHAGOSOMES; PHARYNGEAL NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; RATS; TOR SERINE-THREONINE KINASES; TUMOR STEM CELL ASSAY;

EID: 84942907310     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0037     Document Type: Article

References (53)

1. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010;277:3890-903.
2. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Intl J Biochem Cell Biol 2006;38:2018-39.
3. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-108.
4. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-7.
5. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001;15:1661-3.
6. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 1988;130:393-400.
7. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 2004;279:44084-92.
8. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005;280:20457-66.
9. Nadav L, Eldor A, Yacoby-Zeevi O, Zamir E, Pecker I, Ilan N, et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci 2002;115:2179-87.
10. Shteingauz A, Ilan N, Vlodavsky I. Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and alpha-actinin. Cell Mol Life Sci 2014;71:4457-70.
11. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004;117:2249-58.
12. Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N, et al. Human heparanaseislocalizedwithin lysosomesina stable form. Exp Cell Res 2002;281:50-62.
13. Cohen E, Atzmon R, Vlodavsky I, Ilan N. Heparanase processing by lysosomal/endosomal protein preparation. FEBS Lett 2005;579:2334-8.
14. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB, Joyce JA, et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008;283:18167-76.
15. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, Peretz T, et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 2005;280:13568-75.
16. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011;30:253-68.
17. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004;279:23536-41.
18. Egeberg M, Kjeken R, Kolset SO, Berg T, Prydz K. Internalization and stepwise degradation of heparan sulfate proteoglycans in rat hepatocytes. Biochim Biophys Acta 2001;1541:135-49.
19. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis 2011;32:955-63.
20. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012;12:401-10.
21. Arvatz G, Barash U, Nativ O, Ilan N, Vlodavsky I. Post-transcriptional regulation of heparanase gene expression by a 30 AU-rich element. FASEB J 2011;24:4969-76.
22. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008;68:10077-85.
23. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, Ilan N, et al. Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J Biol Chem 2012;287:6668-78.
24. Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007;67:7907-16.
25. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PloS One 2009;4:e5181.
26. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent antitumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011;104:635-42.
27. Barash U, Zohar Y, Wildbaum G, Beider K, Nagler A, Karin N, et al. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 2014;28:2178-87.
28. Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ O, et al. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 2010;24:1239-48.
29. Zcharia E, Metzger S, Chajek-Shaul L T, Aingorn H, Elikn M, Friedmann Y, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004;18:252-63.
30. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 2009;69:1758-67.
31. Ostapoff KT, Awasthi N, Cenik BK, Hinz S, Dredge K, Schwarz RE, et al. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther 2013;12:1190-201.
32. Boyango I, Barash U, Naroditsky I, Li JP, Hammond E, Ilan N, et al. Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res 2014;74:4504-14.
33. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol 2014;24:400-6.
34. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-52.
35. Ravikumar B, Futter M, Jahreiss L, Korolchuk VI, Lichtenberg M, Luo S, et al. Mammalian macroautophagy at a glance. J Cell Sci 2009;122:1707-11.
36. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Intl J cancer 2008;123:2566-73.
37. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006;8:1055-61.
38. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455-63.
39. Roucourt B, Meeussen S, Bao J, Zimmermann P, David G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Research 2015;25:412-28.
40. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem 2013;288:10093-9.
41. Dunlop EA, Tee AR. mTOR and autophagy: A dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol 2014;36:121-9.
42. Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther 2011;131:130-41.
43. Korolchuk VI, Saiki S, Lichtenberg M, Siddiqi FH, Roberts EA, Imarisio S, et al. Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol 2011;13:453-60.
44. Korolchuk VI, Rubinsztein DC. Regulation of autophagy by lysosomal positioning. Autophagy 2011;7:927-8.
45. Efeyan A, Comb WC, Sabatini DM. Nutrient-sensing mechanisms and pathways. Nature 2015;517:302-10.
46. Efeyan A, Sabatini DM. Nutrients and growth factors in mTORC1 activation. Biochem Soc Trans 2013;41:902-5.
47. Sanderson RD, Yang Y, Kelly T, Macleod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005;96:897-905.
48. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006;13:2101-11.
49. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007;13:2057-73.
50. Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, et al. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem 2012;55:3804-13.
51. Zhang L, Ngo JA, Wetzel MD, Marchetti D. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia 2015;17:101-13.
52. Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, et al. The autophagic paradox in cancer therapy. Oncogene 2012;31:939-53.
53. Ding Z, Wang X, Khaidakov M, Liu S, Dai Y, Mehta JL. Degradation of heparan sulfate proteoglycans enhances oxidized-LDL-mediated autophagy and apoptosis in human endothelial cells. Biochem Biophys Res Commun 2012;426:106-11.